Dare Bioscience (NASDAQ:DARE) Earns Buy Rating from Analysts at Aegis

Equities researchers at Aegis started coverage on shares of Dare Bioscience (NASDAQ:DARE) in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage set a “buy” rating on the biotechnology company’s stock.

Other analysts have also recently issued research reports about the stock. ValuEngine upgraded shares of Dare Bioscience from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd. Maxim Group reiterated a “buy” rating and issued a $3.00 price target on shares of Dare Bioscience in a report on Thursday, May 16th.

NASDAQ:DARE traded up $0.03 during trading hours on Thursday, hitting $0.82. The company had a trading volume of 24,789 shares, compared to its average volume of 212,658. The company has a market capitalization of $13.78 million, a PE ratio of -0.75 and a beta of 1.96. The stock has a 50-day moving average price of $0.79 and a 200 day moving average price of $0.95. Dare Bioscience has a 52 week low of $0.60 and a 52 week high of $3.25.

Dare Bioscience (NASDAQ:DARE) last released its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.09). On average, sell-side analysts forecast that Dare Bioscience will post -0.88 EPS for the current fiscal year.

An institutional investor recently raised its position in Dare Bioscience stock. Susquehanna International Group LLP lifted its stake in Dare Bioscience Inc (NASDAQ:DARE) by 293.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,770 shares of the biotechnology company’s stock after purchasing an additional 31,900 shares during the quarter. Susquehanna International Group LLP owned 0.26% of Dare Bioscience worth $36,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 5.28% of the stock is currently owned by institutional investors and hedge funds.

Dare Bioscience Company Profile

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.

Further Reading: Rule of 72

The Fly

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.